ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive
09 July 2024 - 1:30PM
Business Wire
New appointment brings global financial and
operational experience in life sciences to support continued
advancement of ReAlta’s EPICC Technology Platform
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a
mid-stage clinical biotech company dedicated to saving lives by
rebalancing the inflammatory response to address life-threatening
diseases, today announced the appointment of Emma Reeve to its
Board of Directors, effective immediately.
“We are very pleased to welcome Emma Reeve to our Board of
Directors,” said Buzz Heidt, Chairman of ReAlta’s Board of
Directors. "As ReAlta continues to advance our programs towards
commercial launch in markets around the world, Emma's diverse
global experience and deep knowledge of capital markets and
financial strategies will help guide and strengthen our plans to
deliver novel therapies to the patients that urgently need
them.”
“I am impressed with the remarkable progress ReAlta has made to
advance multiple programs into the clinic,” said Ms. Reeve. “I am
excited to take on this role and contribute to the company’s
mission to address life threatening acute inflammatory and rare
diseases.”
Emma Reeve
Emma Reeve is an accomplished biopharmaceutical executive with
more than 30 years of global financial experience across
pharmaceutical, medical device, and bio-pharma companies. Most
recently, Ms. Reeve served as Chief Financial Officer of
Constellation Pharmaceuticals, Inc., a development-stage oncology
company, prior to its acquisition by MorphoSys AG in 2021. She led
Constellation’s IPO in 2018.
Prior to Constellation, Ms. Reeve acted as interim Chief
Financial Officer and Corporate Controller of Parexel
International, a global biopharmaceutical services company, where
she was responsible for all aspects of finance, investor relations,
procurement, and facilities. In this role, she led the finance
aspects of a sell-side process which culminated in an agreement to
take the company private in a $5 billion leveraged buy-out. Earlier
in her career, Ms. Reeve served as Chief Financial Officer of both
Inotek Pharmaceuticals and Aton Pharma. Additionally, she held
senior finance and operational roles at Bristol Myers Squibb,
Merck, and Novartis.
Ms. Reeve is currently Chair of the Board of Editas Medicine and
serves on the Board of PTC Therapeutics and Aadi Bioscience, all
public biotechnology companies. In addition, she serves on the
Board of Directors for Cardurion Pharma. Ms. Reeve holds a B.Sc. in
computer science from Imperial College, University of London and is
an associate of the Institute of Chartered Accountants in England
and Wales.
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a mid-stage clinical biotech
company dedicated to saving lives by rebalancing the inflammatory
response to address life threatening acute inflammatory and rare
diseases. The Company’s EPICC peptides are based on research into
the human astrovirus, HAstV-1, which causes a non-inflammatory,
self-limiting gastroenteritis unique among viruses by inhibiting
components of the innate immune system. ReAlta’s therapeutic
peptides leverage these virus-derived mechanisms to rebalance
complement and inflammatory processes in the body. The company’s
pipeline is led by RLS-0071, which has received IND clearance by
the U.S. Food and Drug Administration (FDA) for the treatment of
acute exacerbations of chronic obstructive pulmonary disease and
acute graft-versus-host disease, and IND clearance, Orphan Drug
Designation, and Fast Track Designation by the FDA, and Orphan Drug
Designation by the European Medicines Agency, for the treatment of
hypoxic-ischemic encephalopathy (HIE). The company launched in 2018
and is located in Norfolk, Virginia. For more information, please
visit www.realtalifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709212380/en/
Media and Investor Contact: John Rickman Chief Financial
Officer jrickman@realtals.com